Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

Terry Chrisomalis
Investing Group Leader
(17min)

Summary

  • Spyre Therapeutics, Inc.'s SPY002 and SPY072 drug candidates showed strong safety and TL1A inhibition in a phase 1 study, supporting advancement to phase 2 clinical development.
  • SPY002 targets ulcerative colitis, while SPY072 will address multiple rheumatological conditions, with large market opportunities and key data readouts expected in 2025-2026.
  • The extended half-life of these candidates could enable infrequent dosing, potentially offering a best-in-class advantage over competitors in the autoimmune and inflammatory disorders space.
  • SYRE had $565 million in cash as of March 31st 2025; enough cash on hand to fund its operations into the 2nd half of 2028.
  • Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »

Scientist checking quality of medicine in the modern inspection laboratory in a medicine production factory

leolintang

Spyre Therapeutics, Inc. (NASDAQ:SYRE) announced positive results from its phase 1 trial using SPY002 and SPY072 for the treatment of patients with autoimmune and inflammatory disorders. It did so with the use of SPY002 and SPY072, which

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.46K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About SYRE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on SYRE

Related Stocks

SymbolLast Price% Chg
SYRE
--
Compare

Trending Analysis

Trending News